Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02546154
Recruitment Status : Active, not recruiting
First Posted : September 10, 2015
Last Update Posted : September 5, 2018
Sponsor:
Collaborator:
BioStata
Information provided by (Responsible Party):
Pharmacosmos A/S ( Pharmacosmos UK Ltd )

Brief Summary:
The objective is to monitor and quality assure the efficacy, including effects on quality of life, and safety of Monofer® in Chronic Kidney Disease and Inflammatory Bowel Disease patient populations when Monofer® is used according to the Monofer® label (Summary of Product Characteristics, SPC) in current clinical practice and where standard routines are being followed.

Condition or disease Intervention/treatment
Iron Deficiency Anaemia Drug: 10% Iron Isomaltoside 1000

Detailed Description:

Intravenous (IV) iron is a well-tolerated and efficacious treatment of iron deficiency anaemia in conditions such as Chronic Kidney Disease (CKD) and Inflammatory Bowel Disease (IBD). Several studies in CKD and IBD patients have shown that IV iron is superior to oral iron, most likely explained by decreased uptake and poor compliance (due to gastrointestinal side-effects) when using oral iron.

The patented Iron Isomaltoside 1000 (Monofer®) has been developed to overcome the current limitations of IV iron drugs with regards to safety and convenience of use. The possibility to administer Monofer® at high single doses (up to 20 mg/kg) reduces the number of treatment visits needed for full iron correction, which is cost-effective, resource and time-sparing, and a reduced drug exposure frequency decreases the risk of side-effects such as infusion reactions.

The objective of the study is to monitor and quality assure the efficacy, including effects on quality of life, and safety of Monofer® in CKD and IBD patient populations when Monofer® is used according to the Monofer® label (Summary of Product Characteristics, SPC) in current clinical practice and where standard routines are being followed. The scientific rationale being to fulfill a need for systematic information/auditing on applied practice including both short and long-term experience with the use of IV iron in different hospital settings and in current clinical practice. The outcome will provide an evidence base for optimised treatment procedures in terms of safety and efficacy.

The total duration of the study per site is approximately 21 months, which includes a 6 months enrollment period, a prospective observation period of at least 12 months, and a period of maximum 3 months prior to the last blood test. Patients will only attend hospital visits planned as part of their standard treatment and they will receive treatment as a part of standard care and according to the doctor's discretion. The number of patient visits depends on the number of Monofer® treatment courses needed during the study period. Each patient can receive one or more treatment courses during 12 months after informed consent. The last blood test will be taken after the last Monofer® treatment course which might occur 13-15 months after informed consent. Study termination will occur once the 12 months observational period has been completed for all patients and the last blood test has been collected from the last Monofer® treated patient in the study. Each treatment course can consist of one or more Monofer® administrations. For each administration of Monofer® either intravenous infusion or injection can be used. Pre- and post-treatment blood tests according to standard treatment and quality of life assessments for fatigue symptoms (FACIT-Fatigue and IBD-F Scales) are a part of the Monofer® treatment course. Laboratory assessments, i.e. anaemia work-up/treatment evaluation, shall be a part of local standard practice. The protocol does not accept any additional samples outside current local standard practice to be taken.

Clinical data management will be performed in accordance with applicable standards and data cleaning procedures. The collected data will systematically be entered into an electronic case report form (eClinicalOS, myEDC, license by BioStata Aps Denmark). The sources of information are the relevant treatment and laboratory results obtained from patient records as well as the quality of life questionnaires for fatigue symptoms. The data will be evaluated by the Pharmacosmos Medical Affairs teams and an external Data Management vendor located in a country within the European Union.


Layout table for study information
Study Type : Observational
Actual Enrollment : 359 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Non-interventional Study of the Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With the Intravenous Iron Monofer® (10% Iron Isomaltoside 1000)
Actual Study Start Date : January 22, 2016
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Iron

Group/Cohort Intervention/treatment
CKD, iron deficiency anaemia
10% Iron Isomaltoside 1000 administered intravenously to Chronic Kidney Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
Drug: 10% Iron Isomaltoside 1000
Standard clinical practice and following the Monofer® label (SPC)
Other Name: Monofer®

IBD, iron deficiency anaemia
10% Iron Isomaltoside 1000 administered intravenously to Inflammatory Bowel Disease patients in doses at the doctor's discretion for treatment of iron deficiency anaemia.
Drug: 10% Iron Isomaltoside 1000
Standard clinical practice and following the Monofer® label (SPC)
Other Name: Monofer®




Primary Outcome Measures :
  1. Time to relapse of iron deficiency anaemia [ Time Frame: From screening until 12 months ]

Secondary Outcome Measures :
  1. Change in scores for fatigue symptoms [ Time Frame: Immediately before to earliest 4 weeks after each treatment course during 12 months ]
  2. Change in anaemia-related blood parameter levels (haemoglobin, iron parameters) [ Time Frame: Immediately before to earliest 4 weeks after each treatment course during 12 months ]
  3. IV iron dose (total needed dose per treatment course) [ Time Frame: From screening until 12 months ]
  4. Number and seriousness of Adverse Drug Reactions [ Time Frame: From screening until 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients ≥18 years of age diagnosed with iron deficiency anaemia as a consequence of CKD or IBD.
Criteria

Inclusion Criteria:

  • Patients diagnosed with iron deficiency anaemia as a consequence of CKD or IBD (on the basis of local definition or clinical judgement), treated on the doctor's discretion with Monofer® as standard treatment according to current practice

Exclusion Criteria:

  • Patients diagnosed with both CKD and IBD

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02546154


Locations
Layout table for location information
United Kingdom
Royal Devon and Exeter Hospital NHS Foundation Trust
Exeter, United Kingdom, EX2 5DW
Sponsors and Collaborators
Pharmacosmos UK Ltd
BioStata
Investigators
Layout table for investigator information
Study Chair: Sylvia Simon, PhD Pharmacosmos A/S
Principal Investigator: Jason Moore, BMedSci, BMBS, FRCP Royal Devon and Exeter Hospital NHS Foundation Trust

Layout table for additonal information
Responsible Party: Pharmacosmos UK Ltd
ClinicalTrials.gov Identifier: NCT02546154     History of Changes
Other Study ID Numbers: Monofer-NIS-07
First Posted: September 10, 2015    Key Record Dates
Last Update Posted: September 5, 2018
Last Verified: September 2018

Keywords provided by Pharmacosmos A/S ( Pharmacosmos UK Ltd ):
Iron
Anaemia
Anaemia, Iron-Deficiency
Kidney Diseases
Inflammatory Bowel Diseases
Fatigue

Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Anemia, Iron-Deficiency
Deficiency Diseases
Hematologic Diseases
Anemia, Hypochromic
Iron Metabolism Disorders
Metabolic Diseases
Malnutrition
Nutrition Disorders
Iron
Iron isomaltoside 1000
Ferric Compounds
Trace Elements
Micronutrients
Nutrients
Growth Substances
Physiological Effects of Drugs
Hematinics